BioCryst Pharmaceuticals (NASDAQ:BCRX) Given Outperform Rating at Royal Bank of Canada

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “outperform” rating reaffirmed by analysts at Royal Bank of Canada in a research note issued on Tuesday,Benzinga reports. They currently have a $11.00 price target on the biotechnology company’s stock, up from their previous price target of $10.00. Royal Bank of Canada’s target price indicates a potential upside of 35.72% from the stock’s current price.

A number of other analysts also recently weighed in on BCRX. Evercore ISI increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday. Needham & Company LLC boosted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays increased their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Finally, Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday. They issued an “outperform” rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $15.57.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX traded down $0.19 during midday trading on Tuesday, hitting $8.11. 951,574 shares of the stock were exchanged, compared to its average volume of 2,933,177. The business’s 50-day moving average price is $8.03 and its 200 day moving average price is $7.84. The stock has a market capitalization of $1.68 billion, a price-to-earnings ratio of -13.29 and a beta of 1.75. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The business’s revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.28 earnings per share. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.36 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCRX. Xponance Inc. boosted its holdings in BioCryst Pharmaceuticals by 9.1% in the fourth quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 1,242 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares in the last quarter. Sei Investments Co. grew its position in BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock valued at $430,000 after purchasing an additional 1,537 shares during the period. Captrust Financial Advisors grew its position in BioCryst Pharmaceuticals by 19.4% in the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 2,644 shares during the period. Finally, Creative Planning increased its stake in BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock valued at $375,000 after purchasing an additional 2,734 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.